+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Diarrhea - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762913
  • Report
  • April 2019
  • Region: Global
  • 142 pages
  • VPA Research


  • Akthelia Pharmaceuticals
  • AzurRx BioPharma Inc
  • Kaleido Biosciences Inc
  • Nippon Shinyaku Co Ltd
  • Prokarium Ltd
  • Summit Therapeutics Plc
  • MORE

Diarrhea pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Diarrhea R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Diarrhea report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Diarrhea as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Diarrhea with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Diarrhea pipeline Profiled in detail

Key players actively participating in Diarrhea pipeline are profiled along with their R&D progress in Diarrhea treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Diarrhea pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Diarrhea treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Diarrhea pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Diarrhea pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Diarrhea pipeline study
  • All recent news and developments related to Diarrhea drugs are provided
Note: Product cover images may vary from those shown


  • Akthelia Pharmaceuticals
  • AzurRx BioPharma Inc
  • Kaleido Biosciences Inc
  • Nippon Shinyaku Co Ltd
  • Prokarium Ltd
  • Summit Therapeutics Plc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Diarrhea Disease Overview

3. Diarrhea R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Diarrhea Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Diarrhea Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Diarrhea companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Diarrhea Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Akthelia Pharmaceuticals
  • Albireo Pharma
  • Allergan Plc
  • Anatara Lifesciences Limited
  • Ardelyx Inc
  • AzurRx BioPharma Inc
  • Bharat Biotech International Ltd
  • Boston Pharmaceuticals Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • Cosmo Pharmaceuticals NV
  • Ferring International Center SA (Rebiotix Inc)
  • Glycosyn LLC
  • GP Pharm SA
  • Kaleido Biosciences Inc
  • LTT Bio-Pharma Co
  • Miyarisan Pharmaceutical
  • Napo Pharmaceuticals In
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • Orphomed Inc
  • Pfizer Inc
  • Prokarium Ltd
  • Protagonist Therapeutics Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • RxBio Inc
  • Scandinavian Biopharma Holding AB
  • Summit Therapeutics Plc
  • Synthetic Biologics Inc
  • Syntiron LLC
  • Tasly Pharmaceutical Group Co Ltd
  • VenatoRx Pharmaceuticals Inc
  • Zealand Pharma
Note: Product cover images may vary from those shown